The latest price information for the original and generic drugs of gilitinib

Giritinib, as a targeted drug for the treatment of patients with FLT3 mutation-positive acute myeloid leukemia (AML), has attracted much attention worldwide in recent years. The drug's potent inhibitory effect on FLT3 kinase activity has significantly controlled the progression of the disease and brought significant clinical benefits to patients. Multiple clinical trials have confirmed that giritinib can significantly extend the overall survival of patients and improve the complete response rate. This article will give you a detailed introduction to the latest price information of the original drug and generic drugs of giritinib.

Due to the high research and development costs and the fact that it has not yet been included in the medical insurance catalog, the price of the original drug gilitinib in the domestic market is relatively high, roughly around 25,000 yuan per box. Specific prices may vary depending on regions, pharmacies and other factors, so patients are advised to consult themselves.

Fortunately, however, generic versions of giritinib are now on the market. These generic drugs have obvious price advantages over original drugs, providing patients with more choices. For example, the generic version of giritinib produced by Lucius in Laos sells for about 3,000 per box. In addition, Lao Daxiong Pharmaceutical and Lao ASEAN Pharmaceutical also produce generic versions of giritinib, which are also affordable. These generic drugs have been approved by the government and are officially marketed drugs with guaranteed quality. However, despite the price advantage of generic drugs, patients still need to be cautious when purchasing them. In order to ensure the quality and efficacy of drugs, patients are advised to choose formal channels to purchase, and carefully check the drug manufacturer, approval number and other information.

In general, giritinib, as a targeted drug with significant efficacy and good safety profile, brings hope to patients with FLT3 mutation-positive acute myeloid leukemia. Regardless of whether they choose original drugs or generic drugs, patients should use them under the guidance of a doctor to ensure therapeutic efficacy and safety.